Can Claims, Misleading Information, and Manufacturing Issues Regarding Dietary Supplements Be Improved in the United States?
- 1 September 2005
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 314 (3) , 939-944
- https://doi.org/10.1124/jpet.105.085712
Abstract
The safety and effectiveness of over-the-counter (OTC) drugs are assessed through the Food and Drug Administration9s (FDA9s) OTC drug review. Prescription drugs are approved through the rigorous new drug application (NDA) process. In contrast, dietary supplements are regulated as foods, and the FDA must determine that a dietary supplement ingredient poses a “significant or unreasonable risk of illness or injury” instead of requiring the manufacturer to provide safety data. According to the FDA, there are more than 29,000 different dietary supplements available to consumers today. This momentum has its roots in consumer interest in health and self-care and suggests that Americans are searching for alternatives to conventional foods for physical and mental well being. The Committee on the Framework for Evaluating the Safety of Dietary Supplements was formed under the auspices of the Food and Nutrition Board that produced a report entitled Dietary Supplements: A Framework for Evaluating Safety. Categories of specific information identified for use are 1) human data, 2) animal studies, 3) in vitro experiments, and 4) information on related substances. Several factors were identified to guide the FDA in applying the framework. Two of these factors are expressed as follows: 1) “the appropriate scientific standard to be used to overturn this basic assumption of safety is to demonstrate significant or unreasonable risk, not prove that an ingredient is unsafe”; and 2) “approaches taken by diverse organizations and governmental bodies, both within and outside the United States, which evaluate the safety and at times efficacy of dietary supplement ingredients, vary in their relevance to the protection of the American public from risks associated with consumption of dietary supplement ingredients”.This publication has 8 references indexed in Scilit:
- American Society for Clinical Pharmacology and Therapeutics Position Statement on Dietary Supplement Safety and Regulation*Clinical Pharmacology & Therapeutics, 2005
- Emerging Credentialing Practices, Malpractice Liability Policies, and Guidelines Governing Complementary and Alternative Medical Practices and Dietary Supplement RecommendationsArchives of internal medicine (1960), 2005
- Effects of dietary supplements on induction and inhibition of cytochrome P450s protein expression in ratsFood and Chemical Toxicology, 2004
- Complementary and integrative medical therapies, the FDA, and the NIH: definitions and regulationDermatologic Therapy, 2003
- Position of The American Dietetic Association: The Impact of Fluoride on HealthJournal of the American Dietetic Association, 2001
- Position of the American Dietetic Association: Food Fortification and Dietary SupplementsJournal of the American Dietetic Association, 2001
- Position of The American Dietetic Association: Vitamin and Mineral SupplementationJournal of the American Dietetic Association, 1996
- Industry invites regulation: the passage of the Pure Food and Drug Act of 1906.American Journal of Public Health, 1985